30,869 results match your criteria Graft Versus Host Disease


Crowdsourcing to delineate skin affected by chronic graft-vs-host disease.

Skin Res Technol 2019 Feb 20. Epub 2019 Feb 20.

Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.

Background: Estimating the extent of affected skin is an important unmet clinical need both for research and practical management in many diseases. In particular, cutaneous burden of chronic graft-vs-host disease (cGVHD) is a primary outcome in many trials. Despite advances in artificial intelligence and 3D photography, progress toward reliable automated techniques is hindered by limited expert time to delineate cGVHD patient images. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/srt.12688DOI Listing
February 2019

Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know.

Arch Pathol Lab Med 2019 Feb 20. Epub 2019 Feb 20.

From the Department of Dermatology, Saint Louis University, St Louis, Missouri (Dr Abate);the Departments of Dermatology (Dr Battle),and Pathology (Drs Gardner and Shalin),University of Arkansas for Medical Sciences, Little Rock; and the Department of Dermatology, University of Mississippi Medical Center, Jackson (Dr Emerson).

Context.—: Fatal dermatologic diseases and ones with high morbidity can occur in the inpatient setting. In such cases, prompt and accurate assessment of a bedside skin biopsy is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2018-0239-RADOI Listing
February 2019

Passive transfer of allergic encephalomyelitis in rats: a tool for drug mechanism studies and detecting late-acting immunosuppressants.

Inflammopharmacology 2019 Feb 16. Epub 2019 Feb 16.

Department of Medicine, University of California, Los Angeles, CA, 90024, USA.

1. A strategy is described for evaluating drugs against different phases in the development of an auto allergic disease, experimental allergic encephalomyelitis. It is based on a cell transfer technique whereby the disease is passively transferred with lymphoid cells from actively immunized donor rats to normal syngeneic rats = passive recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10787-019-00565-wDOI Listing
February 2019

Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India.

J Clin Immunol 2019 Feb 18. Epub 2019 Feb 18.

Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, 320, Padma complex, Anna salai, Teynampet, Chennai, Tamil Nadu, 600035, India.

Haploidentical stem cell transplantation (haplo SCT) has emerged as an acceptable alternative to matched family donor transplantation for children diagnosed to have primary immune deficiency disorders (PIDs). We present data over 4 years on the challenges and efficacy of unmanipulated T cell replete haplo SCTs with post-transplant cyclophosphamide (PTCy) in children diagnosed to have PIDs. We performed a retrospective study in the pediatric blood and marrow transplantation unit where all children less than 18 years of age diagnosed to have PIDs and who underwent haplo SCT with PTCy from January 2014 to February 2018 were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10875-019-00600-zDOI Listing
February 2019

Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System.

Front Immunol 2019 1;10:38. Epub 2019 Feb 1.

GMP Facility, DFG-Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengeneering, Technische Universität Dresden, Dresden, Germany.

Adoptive transfer of T regulatory cells (Treg) has been successfully exploited in the context of graft-versus-host disease, transplantation, and autoimmune disease. For the majority of applications, clinical administration of Treg requires laborious expansion and typically involves open handling for culture feeds and repetitive sampling. Here we show results from our approach to translate manual Treg manufacturing to the fully closed automated CliniMACS Prodigy® system reducing contamination risk, hands-on time, and quality variation from human intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369367PMC
February 2019
1 Read

Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models.

Cell Mol Immunol 2019 Feb 18. Epub 2019 Feb 18.

Laboratory for Reproductive Immunology, NHC Key Lab of Reproduction Regulation (Shanghai Institute of Planned Parenthood Research), Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University Shanghai Medical College, Shanghai, China.

Mesenchymal stem cells (MSCs), which are pluripotent cells with immunomodulatory properties, have been considered good candidates for the therapy of several immune disorders, such as inflammatory bowel diseases, concanavalin A-induced liver injury, and graft-versus-host disease. The embryo is a natural allograft to the maternal immune system. A successful pregnancy depends on the timely extinction of the inflammatory response induced by embryo implantation, followed by the switch to a tolerant immune microenvironment in both the uterus and the system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41423-019-0204-6DOI Listing
February 2019

Aurora A controls CD8 T cell cytotoxic activity and antiviral response.

Sci Rep 2019 Feb 18;9(1):2211. Epub 2019 Feb 18.

Servicio de Inmunología, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain.

Aurora A is a serine/threonine kinase whose role in cell cycle progression and tumour generation has been widely studied. Recent work has revealed an unexpected function for Aurora A during CD4 T cell activation and, also, in graft versus host disease development. However, it remains unknown whether Aurora A is involved in CD8 T cell effector function and in cytotoxic T lymphocyte-mediated antiviral response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38647-yDOI Listing
February 2019

ABO Blood Grouping Mismatch in Hematopoietic Stem Cell Transplantation and Clinical Guides.

Int J Hematol Oncol Stem Cell Res 2018 Oct;12(4):322-328

Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Hematopoietic stem cell transplantation (HSCT) is a useful treatment. In contrast to solid organ transplantations, the use of ABO blood group mismatch is acceptable in HSCT. Immediate or late hemolytic reactions, pure red cell aplasia, delayed red blood cell recovery, and graft-versus -host disease are the results of this situation. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375375PMC
October 2018

Dendritic Cell Regulation of Graft-Vs.-Host Disease: Immunostimulation and Tolerance.

Front Immunol 2019 1;10:93. Epub 2019 Feb 1.

Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, United States.

Graft-vs.-host disease (GVHD) remains a significant cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Significant progresses have been made in defining the dichotomous role of dendritic cells (DCs) in the development of GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367268PMC
February 2019
1 Read

Oral rehabilitation in a patient with sclerotic-phenotype chronic graft versus host disease: a case report.

Quintessence Int 2019 ;50(3):208-213

Acute myeloid leukemia is a bone marrow malignancy in which blasts count increases by more than 20% in the bone marrow. Allogeneic hematopoietic stem cell transplantation (alloHCT) is a treatment option for these patients with high risk of graft versus host disease (GVHD) development. Chronic GVHD (cGVHD) often mimics a variety of autoimmune conditions such as systemic lupus erythematous or systemic sclerosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3290/j.qi.a41973DOI Listing
January 2019

VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients.

BMJ Open 2019 Feb 15;9(2):e026093. Epub 2019 Feb 15.

Département des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.

Introduction: Immune reconstitution after haematopoietic stem cell transplantation (HSCT) is a complex and dynamic process, varying from a state of nearly complete immunosuppression to an expected full immune recovery. Specific vaccination guidelines recommend reimmunisation after HSCT but data regarding vaccine efficacy in this unique population are scarce. New immune functional assays could enable prediction of vaccine response in the setting of HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-026093DOI Listing
February 2019
1 Read

Non-myeloablative Matched Sibling Donor Hematopoietic Cell Transplantion in Children and Adolescents with Sickle Cell Disease.

Biol Blood Marrow Transplant 2019 Feb 14. Epub 2019 Feb 14.

Section of Oncology/BMT, Departments of Oncology and Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Canada.

Sickle cell disease (SCD) is a potentially debilitating hemoglobinopathy associated with early mortality. The only established curative therapy is hematopoietic cell transplantation (HCT)with a matched sibling donor (MSD). The National Institutes of Health (NIH) nonmyeloablative regimen of alemtuzumab/300 cGy total body irradiation and prolonged sirolimus exposure for graft-versus-host disease (GVHD) prophylaxis was administered to 16 children and adolescents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.011DOI Listing
February 2019

Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model.

EBioMedicine 2019 Feb 13. Epub 2019 Feb 13.

Laboratory for Human Disease Models, RIKEN Center for Integrative Medical Sciences, Yokohama 230-0045, Japan. Electronic address:

Background: Graft-versus host disease (GVHD) is a complication of stem cell transplantation associated with significant morbidity and mortality. Non-specific immune-suppression, the mainstay of treatment, may result in immune-surveillance dysfunction and disease recurrence.

Methods: We created humanised mice model for chronic GVHD (cGVHD) by injecting cord blood (CB)-derived human CD34CD38CD45RA haematopoietic stem/progenitor cells (HSPCs) into hIL-6 transgenic NOD/SCID/Il2rgKO (NSG) newborns, and compared GVHD progression with NSG newborns receiving CB CD34 cells mimicking acute GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2019.02.001DOI Listing
February 2019
2 Reads

Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myeloid leukemia after single cord blood transplantation.

Biol Blood Marrow Transplant 2019 Feb 13. Epub 2019 Feb 13.

Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

The different effects of pre-engraftment syndrome (PES) and acute graft-versus-host disease (GVHD) on transplant outcomes after cord blood transplantation (CBT) are unclear. We retrospectively evaluated the impact of PES and acute GVHD on relapse and survival after single CBT for 138 adult patients with hematological malignancies in our institute between 2004 and 2016. Multivariate analysis demonstrated that development of grade III to IV acute GVHD, particularly gut or liver involvement of acute GVHD, significantly contributed to higher non-relapse mortality (P<0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.02.007DOI Listing
February 2019
1 Read

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.

Sci Rep 2019 Feb 14;9(1):2046. Epub 2019 Feb 14.

Department of Hematology, Stem Cell Transplantation Unit, University of Health Sciences,Ankara Oncology Training and Research Hospital, Ankara, Turkey.

Post-transplant cyclophosphamide has become a promising medical option after allogeneic HSCT. In this study we aimed to evaluate the efficacy of cyclophosphamide and cyclosporine combination in acute and chronic graft-versus-host disease (GvHD) prophylaxis in acute myeloid leukemia (AML) cases scheduled for allogeneic hematopoietic stem cell transplantation (allo-HSCT). Retrospective analysis of data from 40 cases who underwent allogeneic HSCT under GvHD prophylaxis with cyclophosphamide and cyclosporine combination between April 2016 and August 2017 was made. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-38644-1
Publisher Site
http://dx.doi.org/10.1038/s41598-019-38644-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376163PMC
February 2019
3 Reads

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.

Leuk Lymphoma 2019 Feb 15:1-7. Epub 2019 Feb 15.

a Department of Pharmacy, The James Cancer Hospital , The Ohio State University Comprehensive Cancer Center , Columbus , Ohio , 43210 , USA.

Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1573996DOI Listing
February 2019
2 Reads

Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.

Klin Onkol 2019 ;32(1):66-69

Background: Allogeneic hematopoietic stem cell transplantation is one of the therapeutic options for patients with relapsed or refractory classic Hodgkins lymphoma (cHL). In the case of dis-ease relapse after transplant, other treatment options are still limited (for example donor lymphocyte infusion, and chemother-apy with brentuximab, bendamustine, or other agents) with uncertain outcomes in terms of patient tolerance and long-term dis-ease remission. One way to achieve remission is administration of the PD-1 inhibitor nivolumab, a PD-1 checkpoint inhibitor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14735/amko2019DOI Listing
January 2019

Chimeric antigen receptor T-cell toxicity.

Curr Opin Pediatr 2019 Feb 11. Epub 2019 Feb 11.

Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Purpose Of Review: Chimeric antigen receptor -(CAR) T-cell therapy has become a commonly used immunotherapy originally used in the treatment of B-cell leukemias but which are now applied broadly across tumor classes. Although high rates of remission are associated with CAR T-cell therapy, toxicities associated with these novel treatment regimens can be lethal if not recognized in a timely manner.

Recent Findings: Cytokine release syndrome and neurotoxicity are the two most common toxicities associated with CAR T-cell therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOP.0000000000000747DOI Listing
February 2019
3 Reads

Current status of graft-versus-host disease after intestinal transplantation.

Curr Opin Organ Transplant 2019 Feb 11. Epub 2019 Feb 11.

Division of Pediatric Transplantation, Department of Surgery, Hillman Center for Pediatric Transplantation, UPMC Children's Hospital of Pittsburgh, Thomas E. Starzl Transplant Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA.

Purpose Of Review: Over the past decades, visceral transplantation has become the standard of care for patients with irreversible intestinal failure who suffer complications of total parenteral nutrition (TPN). Graft-versus-host disease (GVHD) after solid organ transplantation is a rare but often fatal complication with high mortality. GVHD after intestinal transplantation, given the large lymphoid content of the graft, is more frequent compared with other solid organs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOT.0000000000000624DOI Listing
February 2019
6 Reads

Intravenous immunoglobulin treatment: Where do dermatologists stand?

Authors:
Selma Emre

Dermatol Ther 2019 Feb 13:e12854. Epub 2019 Feb 13.

Department of Dermatology, Yildirim Beyazit University, Medical School, Ankara, Turkey.

Intravenous immunoglobulins are therapeutic products, comprising polyclonal IgGs, which are obtained from human plasma pool of healthy blood donors. Despite the lack of FDA approval, the experience of using IVIG in various dermatological diseases increases day by day and exciting results are reported. However, experience with the use of IVIG in dermatological indications are mostly case reports whereas randomized, controlled, double-blind, multicentric studies have not been performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12854DOI Listing
February 2019
1 Read

Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models.

Am J Cancer Res 2019 1;9(1):53-63. Epub 2019 Jan 1.

Department of Medical Physics, University of Wisconsin-Madison Madison, WI 53705, USA.

Imaging of immunotherapy targets using positron emission tomography (PET) can allow for noninvasive monitoring of their dynamic expression and may allow for patient stratification in the future. Therefore, two tracers targeting CTLA-4, one a full antibody and the other a F(ab') fragment, were radiolabeled with Cu and validated in humanized mouse models. Ipilimumab was digested to develop ipilimumab-F(ab'), and both the intact antibody and the fragment were conjugated with NOTA to chelate Cu for PET. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356917PMC
January 2019

Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in T regulatory cells.

JCI Insight 2019 Feb 12. Epub 2019 Feb 12.

Chimeric antigen receptor (CAR) technology can be used to engineer the antigen-specificity of regulatory T cells (Tregs) and improve their potency as an adoptive cell therapy in multiple disease models. As synthetic receptors, CARs carry the risk of immunogenicity, particularly when derived from non-human antibodies. Using an HLA-A*02:01-specific CAR (A2-CAR) encoding a single-chain Fv derived from a mouse antibody, we developed a panel of 20 humanized (h)A2-CARs. Read More

View Article

Download full-text PDF

Source
http://insight.jci.org/articles/view/123672
Publisher Site
http://dx.doi.org/10.1172/jci.insight.123672DOI Listing
February 2019
3 Reads

Targeting PI3Kδ Function For Amelioration of Murine Chronic Graft-Versus-Host Disease.

Am J Transplant 2019 Feb 12. Epub 2019 Feb 12.

Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.

Chronic graft-versus-host disease is a leading cause of morbidity and mortality following allotransplant. Activated donor effector T-cells can differentiate into pathogenic T helper (Th)-17 cells and germinal center -promoting Tfollicular helper cells, resulting in cGVHD. Phosphoinositide-3-kinase-δ, a lipid kinase, is critical for activated T-cell survival, proliferation, differentiation, and metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15305DOI Listing
February 2019
1 Read
5.683 Impact Factor

R707, a Fully Human Antibody Directed Against CC-Chemokine Receptor 7, Attenuates Xenogeneic Acute Graft-Versus-Host Disease.

Am J Transplant 2019 Feb 12. Epub 2019 Feb 12.

Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC.

Acute graft-versus-host disease (aGVHD) remains a barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT). Previously, we demonstrated that CC-Chemokine Receptor 7 (CCR7) is critical for aGVHD pathogenesis but dispensable for beneficial graft-versus-leukemia (GVL) responses. As a result, we evaluated a fully human anti-CCR7 blocking antibody as a new approach to prevent aGVHD in preclinical models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajt.15298DOI Listing
February 2019

FL/GCSF/AMD3100 Mobilized Hematopoietic Stem Cells Induce Mixed Chimerism With Nonmyeloablative Conditioning and Transplantation Tolerance.

Transplantation 2019 Feb 4. Epub 2019 Feb 4.

Institute for Cellular Therapeutics, University of Louisville, Louisville, KY, USA.

Background: Mobilization of hematopoietic stem cells (HSC) has become the preferred approach for HSC transplantation. AMD3100, a competitive inhibitor of C-X-C motif chemokine receptor-4 (CXCR4), has been found to be a rapid mobilizing agent. The present study evaluated approaches to optimize the product collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000002657DOI Listing
February 2019
1 Read

Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.

Ann Hematol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Chinese PLA General Hospital, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, China.

Donor lymphocyte infusion (DLI) might be used prophylactically to reduce relapse after allogeneic hematopoietic stem cell transplantation for very high-risk leukemia/lymphoma without effective targeted therapy. To compare the safety and efficacy of prophylactic DLI for prevention of relapse after allogeneic peripheral blood stem cell transplantation from haploidentical donors (HID-SCT) and matched-sibling donors (MSD-SCT) in patients with very high-risk acute myeloid leukemia (AML), we performed a retrospective analysis in a cohort of 21 HID-SCT and 13 MSD-SCT recipients, displaying similar baseline characteristics except for donor's gender distribution. Grade 2-4 acute graft-versus-host disease (GVHD) at 100-day post-DLI was higher in HID-SCT group than that in MSD-SCT group (59. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03636-8DOI Listing
February 2019
1 Read

Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).

Lancet Infect Dis 2019 Feb 7. Epub 2019 Feb 7.

Department of Cellular Therapy and Allogeneneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden; Karolinska Institutet, Stockholm, Sweden.

Infection is a main concern after haemopoietic stem cell transplantation (HSCT) and a major cause of transplant-related mortality. Some of these infections are preventable by vaccination. Most HSCT recipients lose their immunity to various pathogens as soon as the first months after transplant, irrespective of the pre-transplant donor or recipient vaccinations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1473-3099(18)30600-5DOI Listing
February 2019

Increased splenic human CD4:CD8 T cell ratios, serum human interferon-γ and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized mice.

Transpl Immunol 2019 Feb 8. Epub 2019 Feb 8.

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2252, Australia; Molecular Horizons, University of Wollongong, Wollongong, NSW 2252, Australia; Illawarra Health and Medical Research Institute, Wollongong, NSW 2252, Australia. Electronic address:

Graft-versus-host disease (GVHD) is a frequent complication following allogeneic hematopoietic stem cell transplantation (HSCT) with current therapies limited to general immunosuppression. Humanized mouse models of GVHD are emerging as valuable intermediaries to allow translation of findings from allogeneic mouse models to humans to prevent and treat this disease, but such models require further characterization. In this study, humanized mice were generated by injecting immunodeficient non-obese diabetic severe combined immunodeficiency interleukin (IL)-2 receptor γ common chain null (NSG) mice with human peripheral blood mononuclear cells (hPBMCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trim.2019.02.003DOI Listing
February 2019
1 Read

Commensal microflora in human conjunctiva; characteristics of microflora in the patients with chronic ocular graft-versus-host disease.

Ocul Surf 2019 Feb 8. Epub 2019 Feb 8.

Department of Ophthalmology, Keio University School of Medicine, Japan.

Purpose: To investigate the transformation in the composition of ocular surface microflora. Evidence shows that microbial diversity correlates with autoimmune disorders. Chronic ocular graft-versus-host disease (GVHD) is the lethal complication after hematopoietic stem cell transplantation (HSCT) which influences patients' quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtos.2019.02.001DOI Listing
February 2019
1 Read

First Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation.

Am J Respir Crit Care Med 2019 Feb 11. Epub 2019 Feb 11.

Univ Michigan, Internal Medicine, Ann Arbor, Michigan, United States ;

Rationale: "Non-infectious" pulmonary complications are significant causes of morbidity and mortality post allogeneic hematopoietic cell transplant. Early onset viral reactivations or infections are common after transplant. Whether the first onset viral infection causes "non-infectious" pulmonary complications is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201809-1635OCDOI Listing
February 2019
1 Read

An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation.

Nat Biotechnol 2019 Feb 11. Epub 2019 Feb 11.

Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for multiple disorders, but deficiency and dysregulation of T cells limit its utility. Here we report a biomaterial-based scaffold that mimics features of T cell lymphopoiesis in the bone marrow. The bone marrow cryogel (BMC) releases bone morphogenetic protein-2 to recruit stromal cells and presents the Notch ligand Delta-like ligand-4 to facilitate T cell lineage specification of mouse and human hematopoietic progenitor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41587-019-0017-2DOI Listing
February 2019
3 Reads
41.514 Impact Factor

Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease.

Crit Care Med 2019 Feb 7. Epub 2019 Feb 7.

Medical Intensive Care Unit, Hospital Saint Louis, Assistance Publique - Hôpitaux de Paris, France.

Objectives: Neutropenic enterocolitis occurs in about 5.3% of patients hospitalized for hematologic malignancies receiving chemotherapy. Data from critically ill patients with neutropenic enterocolitis are scarce. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCM.0000000000003687DOI Listing
February 2019
1 Read

[Ressarch Advances of Prevantive and Therapeatic Effect of Mesenchymal Stromal Cells on Graft-Versus-Host Disease--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):283-287

Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China.E-mail:

Objective: Graft-versus-host disease (GVHD) is a frequently encountered serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), it limits the success and widespread use of allo-HSCT. Mesenchymal stem cells (MSCs) are selected as ideal prophylactic and treatment means for GVHD during allo-HSCT due to their unique immunomodulatory and regenerative properties. Herein, the recent research progress about the prevantive and therapeutic effects of MSCs on GVHD and several issues related with the applications of MSC, including whether MSCs increasing risk of primary disease relapse and infection, impact of several clinical parameters on the clinical response to MSCs, and the prevantive and therapeutic effect of MSC-derived extracellular vesicles on GVHD are systematically reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.046DOI Listing
February 2019
5 Reads

[Relationship Between the Change of Microbial Diversity and Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):239-245

Department of Hematology,Guangzhou First People's Hospital,Guangzhou Medical University,Guangzhou 510180,Guangdong Province, China.E-mail:

Objective: To investigate the change of microbial diversity and its relation with gastrointestinal (GI) graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Methods: Fecal samples were collected at the time point of 2 weeks before transplantation (pre-transplant group), 1 month after transplantation (post-tranplant group) and onset of GI GVHD in 65 hematonosis patients, which were also collected in 26 donors and 10 healthy subjects (control group). 16S rRNA was extracted from fecal microbiotas whose V4 variable region was amplified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.039DOI Listing
February 2019

Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease.

Stem Cell Res 2019 Feb 1;35:101401. Epub 2019 Feb 1.

Graduate Program in Molecular and Cellular Biology, University of Massachusetts Amherst, Amherst, MA 01003, United States; Department of Veterinary & Animal Sciences, University of Massachusetts Amherst, Amherst, MA 01003, United States. Electronic address:

The immune-mediated tissue destruction of graft-vs-host disease (GvHD) remains a major barrier to greater use of hematopoietic stem cell transplantation (HSCT). Mesenchymal stem cells (MSCs) have intrinsic immunosuppressive qualities and are being actively investigated as a therapeutic strategy for treating GvHD. We characterized Cymerus™ MSCs, which are derived from adult, induced pluripotent stem cells (iPSCs), and show they display surface markers and tri-lineage differentiation consistent with MSCs isolated from bone marrow (BM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scr.2019.101401DOI Listing
February 2019
1 Read
3.693 Impact Factor

The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.

Leukemia 2019 Feb 8. Epub 2019 Feb 8.

Center for Immunotherapy Research, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.

Graft-versus-host disease (GVHD) is a major barrier to the widespread use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treating hematologic malignancies. Myeloid-derived suppressor cells (MDSCs) have been recognized as crucial immunosuppressive cells in various pathologic settings. Here, we investigated whether the unique functional properties of MDSCs could be harnessed to control allo-HSCT-associated GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0394-zDOI Listing
February 2019
1 Read

Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).

J Clin Med 2019 Feb 6;8(2). Epub 2019 Feb 6.

Department of Internal Medicine V (Hematology/Oncology/Rheumatology), University Hospital Heidelberg, 69120 Heidelberg, Germany.

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment option in intermediate and high risk AML. It is the proof-of-concept for T cell-based immunotherapies in AML based on the graft-versus-leukemia (GvL)-effect, but it also bears the risk of graft-versus-host disease. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2077-0383/8/2/200
Publisher Site
http://dx.doi.org/10.3390/jcm8020200DOI Listing
February 2019
3 Reads

Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.

Infection 2019 Feb 7. Epub 2019 Feb 7.

Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Background: Invasive fungal disease (IFD) and graft-versus-host disease (GVHD) are major causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the impacts of IFD on chronic GVHD remain unknown.

Methods: We conducted a retrospective study of 510 patients with hematologic malignancy undergoing allo-HSCT to explore the effects of IFD on chronic GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s15010-018-01265-3DOI Listing
February 2019
1 Read

Pattern of Dermatological Disease Encountered in a Hematology Ward: A Retrospective Analysis of Dermatology Consultation in a Hematology Ward in a Tertiary Care Center in Saudi Arabia.

Dermatol Res Pract 2019 13;2019:9891270. Epub 2019 Jan 13.

Intermediate Care Unit, King Abdulaziz Medical City (KAMC), National Guard Health Affairs (NGHA), Riyadh, Saudi Arabia.

Skin manifestations are common in hematology ward patients and can result from infection, malignancy, or chemotherapy. The purpose of this study was to identify the most common dermatological problems encountered in the adult hematology ward at King Abdullah Specialist Children Hospital (KASCH). This was retrospective chart review of 78 dermatology consultations based on electronic health records for all inpatients in hematology wards at KASCH between January 2016 and December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/9891270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348816PMC
January 2019
1 Read

BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.

Front Immunol 2018 24;9:3104. Epub 2019 Jan 24.

Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, United States.

A recent approach for limiting production of pro-inflammatory cytokines has been to target bromodomain and extra-terminal (BET) proteins. These epigenetic readers of histone acetylation regulate transcription of genes involved in inflammation, cardiovascular disease, and cancer. Development of BET inhibitors (BETi) has generated enormous interest for their therapeutic potential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.03104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353853PMC
January 2019
1 Read

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

University Hospital Eppendorf, Hamburg, Germany.

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Read More

View Article

Download full-text PDF

Source
http://www.haematologica.org/lookup/doi/10.3324/haematol.201
Publisher Site
http://dx.doi.org/10.3324/haematol.2018.205211DOI Listing
February 2019
3 Reads

Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematological malignancies carrying multidrug-resistance bacteria.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Department of Hematology, Saint Antoine Hospital, Paris, France.

Fecal microbiota transplantation is an effective treatment in recurrent Clostridium difficile infection. Promising results to eradicate multidrug-resistant bacteria have also been reported with this procedure, but there are safety concerns in immunocompromised patients. We report results in 10 adult patients colonized with multidrug-resistant bacteria, undergoing fecal microbiota transplantation before (n=4) or after (n=6) allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.198549DOI Listing
February 2019
3 Reads

Sequential therapy for patients with primary refractory acute myeloid leukemia - historical prospective analysis of the German and Israeli experience.

Haematologica 2019 Feb 7. Epub 2019 Feb 7.

Department I of Internal Medicine, University of Cologne, Germany.

Primary refractory acute myeloid leukemia is associated with a dismal prognosis. The fludarabine, amsacrine, and cytarabine-reduced-intensity conditioning protocol (total body irradiation or treosulfan-based) has been described to be an effective approach in patients with refractory leukemia undergoing allogeneic hematopoietic cell transplantation . A modified protocol (without amsacrine) has been also used recently. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203869DOI Listing
February 2019
1 Read

Dynamics of the Gut Microbiota in Children Receiving Selective or Total Gut Decontamination Treatment During Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Feb 4. Epub 2019 Feb 4.

Department of Medical Microbiology, Leiden University Medical Center, Leiden, the Netherlands; Center for Microbiome Analyses and Therapeutics, Leiden University Medical Center, Leiden, the Netherlands.

Bloodstream infections and Graft-versus-Host disease (GvHD) are common complications after hematopoietic stem cell transplantation (HSCT) procedures, associated with the gut microbiota which acts as a reservoir for opportunistic pathogens. Selective gut decontamination (SGD) and total gut decontamination (TGD) during HSCT have been associated with a decreased risk of developing these complications after transplantation. However, since studies have shown conflicting results, the use of these treatments remain subject of debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.037DOI Listing
February 2019
1 Read

New graft manipulation strategies improved outcome of mismatched stem cell transplantation in children with primary immunodeficiencies.

J Allergy Clin Immunol 2019 Feb 4. Epub 2019 Feb 4.

Molecular and Cellular Immunology Unit, University College London (UCL) Great Ormond Street Institute of Child Health, London, United Kingdom; Blood and Bone marrow transplant Unit, Great Ormond Street Hospital, London, UK.

Background: Mismatched stem cell transplantation is associated with high risk of graft loss, graft versus host disease (GvHD) and transplant related mortality (TRM). Alternative graft manipulation strategies have been employed over the last 11 years to reduce these risks.

Objective: We investigated the outcome of using different graft manipulation strategies among children with primary immunodeficiency (PID). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2019.01.030DOI Listing
February 2019
1 Read

Learning the Dynamic Treatment Regimes from Medical Registry Data through Deep Q-network.

Sci Rep 2019 Feb 6;9(1):1495. Epub 2019 Feb 6.

Department of Electrical Engineering and Computer Engineering, Northeastern University, Boston, MA, 02115, USA.

This paper presents the deep reinforcement learning (DRL) framework to estimate the optimal Dynamic Treatment Regimes from observational medical data. This framework is more flexible and adaptive for high dimensional action and state spaces than existing reinforcement learning methods to model real-life complexity in heterogeneous disease progression and treatment choices, with the goal of providing doctors and patients the data-driven personalized decision recommendations. The proposed DRL framework comprises (i) a supervised learning step to predict expert actions, and (ii) a deep reinforcement learning step to estimate the long-term value function of Dynamic Treatment Regimes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37142-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365640PMC
February 2019
1 Read

High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation.

Blood Adv 2019 Feb;3(3):397-405

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018026039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373751PMC
February 2019
1 Read

[Gingival squamous cell carcinoma diagnosed on the occasion of osteonecrosis of the jaw in a patient with chronic GVHD].

Rinsho Ketsueki 2019 ;60(1):22-27

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University.

A 44-year-old male was diagnosed with acute myeloid leukemia with a complex karyotype. He underwent bone marrow transplantation using an HLA 6/6 antigen-matched sibling donor, but developed chronic graft-versus-host disease (cGVHD) with skin erythema and oral and esophageal lichen planus changes. Treatment with a combination of prednisolone and cyclosporine was initiated on day 646 after transplantation, but oral symptoms persisted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.22DOI Listing
January 2019
2 Reads